NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Relation Therapeutics

Relation Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.relationrx.com/

Last Round

Corporate Funding

Dec 9, 2025

Total Funding Raised

$76.33M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Relation Therapeutics is a biotechnology company that discovers and develops medicines by leveraging its proprietary 'Lab-in-the-Loop' platform which integrates active-graph machine learning, single-cell multi-omics, and genomic data derived from human patient tissue.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Precision Medicine, ML Platforms

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

drug discoveryai drug discoverybiotechtarget identificationlab-in-the-loopmachine learningtherapeutic developmentin silico discoverynewco formationfibrotic diseaseosteoporosisbiotech startupdrug pipelineai-native biotechmulti-omics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Relation Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Relation Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Relation Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingDec 9, 2025
StrategicDec 10, 2024
SeedMar 14, 2024
Early Stage VCJan 19, 2024
SeedJun 9, 2022
Seed
Jul 1, 2021

Key People

Founding team and executive leadership

Benjamin Swerner

COO & Co-founder

Founding Team

Jake P. Taylor-King

Chief Innovation Officer, Head Of Technical Operations, Co-Founder

Founding Team

Jules Marczak

Head Of CEO Office

Executive Team

Lindsay Edwards

Chief Technology Officer and President of Platform

Executive Team

Relation Therapeutics Investors

Notable investors and investment history

Relation Therapeutics investors
InvestorRounds
Magnetic VenturesCorporate Funding, Seed
Deerfield ManagementSeed
Firstminute CapitalSeed
Khosla VenturesSeed
Magnetic VenturesSeed, Corporate Funding
NVenturesCorporate Funding
The Bill & Melinda Gates Foundation TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 1, 2026

    PatchDNA model recognized at NeurIPS AI4D3 workshop.

  • Jan 1, 2026

    Initiated in 2026 to address fibrosis and osteoarthritis.

Relation Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Relation Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Relation Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range130
Year Founded2019
Last FundingDec 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.